These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 20206833

  • 1. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
    Pan C, Liu S, Jiang S.
    J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
    [Abstract] [Full Text] [Related]

  • 2. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L, Tong P, Yu X, Pan C, Zou P, Chen YH, Jiang S.
    Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
    [Abstract] [Full Text] [Related]

  • 3. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M, Vassell R, Yuan C, Keller PW, Ling H, Wang W, Weiss CD.
    J Virol; 2019 Jun 01; 93(11):. PubMed ID: 30894471
    [Abstract] [Full Text] [Related]

  • 4. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
    Yu F, Lu L, Liu Q, Yu X, Wang L, He E, Zou P, Du L, Sanders RW, Liu S, Jiang S.
    Biochim Biophys Acta; 2014 May 01; 1838(5):1296-305. PubMed ID: 24388952
    [Abstract] [Full Text] [Related]

  • 5. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
    Liu S, Lu H, Niu J, Xu Y, Wu S, Jiang S.
    J Biol Chem; 2005 Mar 25; 280(12):11259-73. PubMed ID: 15640162
    [Abstract] [Full Text] [Related]

  • 6. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds.
    Liu S, Wu S, Jiang S.
    Curr Pharm Des; 2007 Mar 25; 13(2):143-62. PubMed ID: 17269924
    [Abstract] [Full Text] [Related]

  • 7. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L.
    J Virol; 2017 Jan 01; 91(1):. PubMed ID: 27795416
    [Abstract] [Full Text] [Related]

  • 8. Peptide and non-peptide HIV fusion inhibitors.
    Jiang S, Zhao Q, Debnath AK.
    Curr Pharm Des; 2002 Jan 01; 8(8):563-80. PubMed ID: 11945159
    [Abstract] [Full Text] [Related]

  • 9. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.
    Zhao L, Tong P, Chen YX, Hu ZW, Wang K, Zhang YN, Zhao DS, Cai LF, Liu KL, Zhao YF, Li YM.
    Org Biomol Chem; 2012 Aug 28; 10(32):6512-20. PubMed ID: 22760295
    [Abstract] [Full Text] [Related]

  • 10. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
    Li W, Lu L, Li W, Jiang S.
    Expert Opin Ther Pat; 2017 Jun 28; 27(6):707-719. PubMed ID: 28076686
    [Abstract] [Full Text] [Related]

  • 11. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L, Gochin M, Liu K.
    Curr Top Med Chem; 2011 Dec 28; 11(24):2959-84. PubMed ID: 22044229
    [Abstract] [Full Text] [Related]

  • 12. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
    Tamamura H, Otaka A, Fujii N.
    Curr HIV Res; 2005 Oct 28; 3(4):289-301. PubMed ID: 16250877
    [Abstract] [Full Text] [Related]

  • 13. A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41.
    Jiang X, Jia Q, Lu L, Yu F, Zheng J, Shi W, Cai L, Jiang S, Liu K.
    Amino Acids; 2016 Dec 28; 48(12):2867-2873. PubMed ID: 27631437
    [Abstract] [Full Text] [Related]

  • 14. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
    Zhu Y, Ding X, Yu D, Chong H, He Y.
    J Virol; 2019 Dec 12; 94(1):. PubMed ID: 31619552
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD.
    AIDS Rev; 2003 Dec 12; 5(4):214-21. PubMed ID: 15012000
    [Abstract] [Full Text] [Related]

  • 17. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides.
    Liu S, Jing W, Cheung B, Lu H, Sun J, Yan X, Niu J, Farmar J, Wu S, Jiang S.
    J Biol Chem; 2007 Mar 30; 282(13):9612-9620. PubMed ID: 17276993
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques.
    Liu S, Jiang S.
    Curr Pharm Des; 2004 Mar 30; 10(15):1827-43. PubMed ID: 15180543
    [Abstract] [Full Text] [Related]

  • 20. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.
    Lai W, Wang C, Yan J, Liu H, Zhang W, Lin B, Xi Z.
    Bioorg Med Chem; 2020 Feb 15; 28(4):115214. PubMed ID: 31932193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.